Legal & General Group Plc grew its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 93,965.5% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 51,736 shares of the company’s stock after buying an additional 51,681 shares during the quarter. Legal & General Group Plc owned approximately 0.05% of Denali Therapeutics worth $1,018,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Baillie Gifford & Co. boosted its stake in shares of Denali Therapeutics by 5.5% in the 1st quarter. Baillie Gifford & Co. now owns 5,192,846 shares of the company’s stock worth $102,247,000 after buying an additional 271,063 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Denali Therapeutics in the first quarter valued at approximately $20,753,000. Bamco Inc. NY boosted its holdings in shares of Denali Therapeutics by 86.4% in the first quarter. Bamco Inc. NY now owns 913,525 shares of the company’s stock valued at $17,987,000 after purchasing an additional 423,525 shares during the period. Lord Abbett & CO. LLC purchased a new stake in shares of Denali Therapeutics in the first quarter valued at approximately $5,604,000. Finally, Allianz Asset Management GmbH raised its stake in Denali Therapeutics by 18.4% in the first quarter. Allianz Asset Management GmbH now owns 236,290 shares of the company’s stock worth $4,653,000 after buying an additional 36,745 shares in the last quarter. 63.99% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages recently commented on DNLI. ValuEngine raised shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Zacks Investment Research downgraded Denali Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, April 17th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $23.25.
Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, August 9th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.39). The firm had revenue of $1.65 million for the quarter, compared to analyst estimates of $3.00 million. equities analysts expect that Denali Therapeutics Inc will post -0.74 earnings per share for the current year.
Denali Therapeutics Company Profile
Denali Therapeutics, Inc engages in the development of portfolio of therapeutic candidates for neurodegenerative diseases. Its programs comprises of lysosomal function pathway, glial biology pathway, and cellular homeostasis. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth in 2013 and is headquartered in San Francisco, CA.
See Also: Investing in Dividend Stocks
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.